114 related articles for article (PubMed ID: 16797413)
1. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jul; 34(7):860-9. PubMed ID: 16797413
[TBL] [Abstract][Full Text] [Related]
2. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2007 Jun; 35(6):920-30. PubMed ID: 17533046
[TBL] [Abstract][Full Text] [Related]
3. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
4. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
[TBL] [Abstract][Full Text] [Related]
5. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
6. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
[TBL] [Abstract][Full Text] [Related]
7. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
8. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2003 Jan; 131(1):82-9. PubMed ID: 12519390
[TBL] [Abstract][Full Text] [Related]
9. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
11. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
12. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade.
Pallasch CP; Ulbrich S; Brinker R; Hallek M; Uger RA; Wendtner CM
Leuk Res; 2009 Mar; 33(3):460-4. PubMed ID: 18838168
[TBL] [Abstract][Full Text] [Related]
13. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells.
Müller MR; Tsakou G; Grünebach F; Schmidt SM; Brossart P
Blood; 2004 Mar; 103(5):1763-9. PubMed ID: 14615377
[TBL] [Abstract][Full Text] [Related]
14. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
Scrivener S; Goddard RV; Kaminski ER; Prentice AG
Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
[TBL] [Abstract][Full Text] [Related]
15. Characterization of mouse CD229 (Ly9), a leukocyte cell surface molecule of the CD150 (SLAM) family.
Sintes J; Vidal-Laliena M; Romero X; Tovar V; Engel P
Tissue Antigens; 2007 Nov; 70(5):355-62. PubMed ID: 17919264
[TBL] [Abstract][Full Text] [Related]
16. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Osterborg A; Wigzell H; Mellstedt H
Br J Haematol; 2000 Nov; 111(2):608-17. PubMed ID: 11122109
[TBL] [Abstract][Full Text] [Related]
17. CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse.
Romero X; Zapater N; Calvo M; Kalko SG; de la Fuente MA; Tovar V; Ockeloen C; Pizcueta P; Engel P
J Immunol; 2005 Jun; 174(11):7033-42. PubMed ID: 15905546
[TBL] [Abstract][Full Text] [Related]
18. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.
Tabarkiewicz J; Giannopoulos K
Transplant Proc; 2010 Oct; 42(8):3293-6. PubMed ID: 20970674
[TBL] [Abstract][Full Text] [Related]
19. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Eling DJ; Casey AE; Kipps TJ; Federoff HJ; Rosenblatt JD
Mol Ther; 2002 Oct; 6(4):455-63. PubMed ID: 12377186
[TBL] [Abstract][Full Text] [Related]
20. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.
Suresh K; Fraser G; Scheid E; Leber B; Gauldie J; Foley R
Leuk Lymphoma; 2006 Feb; 47(2):297-306. PubMed ID: 16321861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
